Apheresis Connectivity Set for Selective Plasma Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical systems for plasma processing often remove essential components along with disease antagonists, exposing patients to risks associated with donated plasma and inefficiencies in targeted plasma modification.
Innovation Solution
A medical system comprising a separation device, a post-processing unit, and a controller that manages the separation and processing of blood components, allowing for the isolation and return of specific components, thereby enhancing the efficiency and safety of plasma processing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If plasma exchange is used to remove disease antagonists, then disease antagonists are removed, but essential components including drugs and proteins are also removed
Solution Approach 1:
The plasma processing is divided into two separate functions: first, disease antagonists are removed through adsorption on the column; second, essential components are recovered and returned to the patient. This segmentation allows selective removal of harmful substances while preserving beneficial components.
Solution Approach 2:
The harmful disease antagonists are extracted from the plasma using an adsorption column with specific ligands that bind selectively to the antagonists. This extraction process separates the harmful substances from the essential components, allowing the latter to be preserved and returned to the patient.
2Object-affected harmful factors
If plasma exchange is used to treat patients, then disease antagonists are removed, but patients are exposed to risks associated with donated plasma
Solution Approach 1:
The harmful disease antagonists are extracted from the patient's plasma through selective adsorption, while the plasma itself is processed and returned to the same patient. This eliminates the need for donated plasma, thereby removing the associated risks of transfusion reactions, infections, and immunological complications.
Solution Approach 2:
An adsorption column with specific ligands acts as an intermediary between the patient's plasma and the treatment outcome. The column selectively binds disease antagonists while allowing essential plasma components to pass through, enabling safe and effective treatment without donor plasma exposure.
3Manufacturing precision
If targeted plasma modification is performed using a dialysis machine, then selective removal of compounds is achieved, but the process is less efficient compared to apheresis system
Solution Approach 1:
The invention merges the selective removal capability of dialysis-based targeted plasma modification with the high efficiency of apheresis systems. The apheresis system rapidly separates plasma from blood components, and the plasma is then subjected to selective adsorption, combining the speed of apheresis with the precision of targeted modification.
Solution Approach 2:
The plasma is first separated from whole blood using apheresis technology as a preliminary step, concentrating the plasma and removing cellular components. This preliminary action prepares the plasma for more efficient and effective targeted modification through adsorption, as the modification process acts on a smaller, concentrated volume of plasma rather than processing entire blood units.
Data Source
AI summary
A medical system may include a separation device configured to separate a material received from a source into two or more components, a post-processing unit in fluid communication with the separation device and configured to isolate at least one of the two or more components, and a controller configured to manage operation of the separation device to separate the material received from the source into the two or more components, to cause the two or more components to move to the post-processing unit, and to return the isolated at least one of the two or more components to the separation device.